What the FDA labels say about taking them together
Nefazodone and nimodipine
Nimodipine's FDA label of August 30, 2024 names nefazodone in its drug interactions section; the nefazodone label PlainMeds reads does not name nimodipine. The nimodipine label: “… protease inhibitors, some azole antimycotics, conivaptan, delavirdine, and nefazodone with nimodipine should generally be avoided because of a risk of significant hypotension.”
Check it at the source: the nefazodone FDA label on DailyMed (effective July 31, 2025, Teva Pharmaceuticals USA, Inc.); the nimodipine FDA label on DailyMed (effective August 30, 2024, Azurity Pharmaceuticals, Inc.).
What does the nefazodone label say about nimodipine?
Nefazodone's label (effective July 31, 2025) does not name nimodipine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Nefazodone Hydrochloride), Teva Pharmaceuticals USA, Inc., effective July 31, 2025 (SPL set 51ff7db5-aaf9-4c3c-86e6-958ebf16b60f), via openFDA; the full label on DailyMed
What does the nimodipine label say about nefazodone?
Nimodipine label, drug interactionsStrong CYP3A4 inhibitors include some members of the following classes: macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., indinavir, nelfinavir, ritonavir, saquinavir), HCV protease inhibitors (e.g., boceprevir, telaprevir), azole antimycotics (e.g., ketoconazole, itraconazole, posaconazole, voriconazole), conivaptan, delavirdine, nefazodone Nimodipine plasma concentration can also be increased in the presence of moderate and weak inhibitors of CYP3A4.
Nimodipine label, warnings and precautionsRisk of Hypotension with Strong CYP3A4 Inhibitors Concomitant use of strong inhibitors of CYP3A4, such as some macrolide antibiotics (e.g., clarithromycin, telithromycin), some HIV protease inhibitors (e.g., indinavir, nelfinavir, ritonavir, saquinavir), some HCV protease inhibitors (e.g., boceprevir, telaprevir), some azole antimycotics (e.g., ketoconazole, itraconazole, posaconazole, voriconazole), conivaptan, delavirdine, and nefazodone with nimodipine should generally be avoided because of a risk of significant hypotension [see Drug Interactions (7.2) ].
Source: FDA drug label (Nymalize), Azurity Pharmaceuticals, Inc., effective August 30, 2024 (SPL set e660fa26-b5c4-4d6d-8887-9e22b6666a10), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Nefazodone | Nimodipine | |
|---|---|---|
| Labeled for | Depression | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $1.17 per tablet 100 mg tablet | $1.37 per capsule 30 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once